The Impact of Daily Carbohydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System (CHOco-AID)
The Impact of Daily CarboHydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System (Medtronic MiniMed 780G): a Multi-center Real-world Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Klemen Dovc, MD, PHD
- Phone Number: +38615229235
- Email: klemen.dovc@kclj.si
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with type 1 diabetes
- Patients aged 7-18 years
- Patients using Medtronic MiniMed 780G with SmartGuard activated
- Patients whose informed consent has been obtained
- >70% CGM data during observational period
Exclusion Criteria:
- Patients with partial clinical remission according to the Hvidovre Study Group definition
- Concomitant treatment with steroids or other drugs known to interfere with blood glucose levels
- Previous diagnosis of psychological or eating disorders
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time in range (%)
Time Frame: 6 months
|
Time spent with sensor glucose between 70 and 180 mg/dl (3.9 and 10 mmol/L)
|
6 months
|
|
Time above range level 1 (%)
Time Frame: 6 months
|
Time spent with sensor glucose between 180 and 250 mg/dl (10.1 and 13.9 mmol/L)
|
6 months
|
|
Time above range level 2 (%)
Time Frame: 6 months
|
Time spent with sensor glucose > 250 mg/dl (13.9 mmol/L)
|
6 months
|
|
Time below range level 1 (%)
Time Frame: 6 months
|
Time spent with sensor glucose between 54 and 70 mg/dl (3.0 and 3.8 mmol/L)
|
6 months
|
|
Time below range level 2 (%)
Time Frame: 6 months
|
Time spent with sensor glucose < 54 mg/dl (3.0 mmol/L)
|
6 months
|
|
Mean sensor glucose (mg/dl or mmol/L)
Time Frame: 6 months
|
6 months
|
|
|
Coefficient of variation (%)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
BMI Z-score
Time Frame: Baseline, 3 months, 6 months
|
Baseline, 3 months, 6 months
|
|
Weight Z-score
Time Frame: Baseline, 3 months, 6 months
|
Baseline, 3 months, 6 months
|
|
Height Z-score
Time Frame: Baseline, 3 months, 6 months
|
Baseline, 3 months, 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHOco-AID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.